Clinical Outcomes of Inhaled Amikacin in Ventilator-Associated Pneumonia: A group randomized controlled, add-on trial
DOI:
https://doi.org/10.47489/szmc.v39i3.697Keywords:
Ventilator-Associated Pneumonia, inhaled amikacin, mechanical ventilation, adjunctive therapy, clinical improvementAbstract
Background: Many clinical trials support the role of inhaled amikacin when combined with IV antibiotics in eradication of bacterial infections, reduce mortality and improve cure in ICU patients. Local contextual data is limited, leaving research gap.
Objective: To assess the effect of inhaled amikacin as an add-on adjunct to the intravenous antibiotics in ventilator- associated pneumonia ICU patients on clinical outcomes.
Methodology: This group randomized controlled add-on trial was conducted to assess the clinical outcomes of inhaled amikacin in VAP treatment. 180 ventilated patients with VAP were recruited from the two Intensive Care Units of Lahore General Hospital Surgical between January to December 2024. Patients were divided into two groups: one received empirical intravenous antibiotics (group N), and the other was administered inhaled amikacin along with empirical intravenous antibiotics (group A). Clinical variables including the duration of mechanical ventilation, length of stay in the ICU and symptom resolution, were compared between the two groups using t-tests and chi-square tests.
Results: Group A had a statistically significant shorter mean duration of mechanical ventilation than patients in Group N (6.8 days vs. 9.36 days, p<0.05). However, there was no significant difference in the mean duration of ICU stay between the two groups (13.9 days vs. 14.3 days, p=0.290). Group A had a higher percentage of symptom resolution compared to Group N (88% vs. 57%, p<0.0001), with an odds ratio of 4.31 (95% CI: 2.13-8.72, p<0.00I) indicating significantly higher odds of symptom resolution with inhaled amikacin.
Conclusion: By using inhaled amikacin as an additional treatment for ventilator-associated pneumonia clinical outcome was improved and the duration of mechanical ventilation was reduced. Ventilator-associated pneumonia (VAP) is a hospital- acquired infection that is linked to high morbidity, mortality, and healthcare expenses. Inhaled amikacin may serve as an adjunctive therapy for VAP, offering targeted delivery and reducing systemic toxicity.
References
Levchenko B, Nazarchuk O, Dmytriiev D, Bahniuk N, Melnychenko M, Dmytriiev K. An adjunctive inhaled amikacin in infants with ventilator-associated pneumonia optimizes the complex antimicrobial therapy: pilot study. Acta Bio Medica. 2023;94(2). https://doi.org/10.23750/abm.v94i2.13910
Rathbun KP, Bourgault AM, Sole ML. Oral microbes in hospital-acquired pneumonia: practice and research implications. Crit Care Nurse. 2022;42(3):47–54. https://doi.org/10.4037/ccn2022672
Lynch JP, Zhanel GG. Pseudomonas aeruginosa pneumonia: evolution of antimicrobial resistance and implications for therapy. Semin Respir Crit Care Med. 2022;43(2):191–218. https://doi.org/10.1055/s-0041-1741019
Sakti PP, Anjarwani S. Weaning failure in mechanical ventilation: a literature review. Heart Sci J. 2023;4(4):5–9. https://doi.org/10.21776/ub.hsj.2023.004.04.2
Mecklenburg A. Failure to wean from mechanical ventilation. In: Intensive Care Fundamentals: Practically Oriented Essential Knowledge for Newcomers to ICUs. Cham: Springer; 2023. P. 241–6. https://doi.org/10.1007/978-3-031-21991-7_18
Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical infectious diseases. 2016;63(5):e61-e111. https://doi.org/10.1093/cid/ciw353
Qin JP, Huang HB, Zhou H, Zhu Y, Xu Y, Du B. Amikacin nebulization for adjunctive therapy of gram-negative pneumonia in mechanically ventilated patients: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2021;11(1):6969. https://doi.org/10.1038/s41598-021-86342-8
Tang R, Luo R, Wu B, Wang F, Song H, Chen X. Effectiveness and safety of adjunctive inhaled antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. J Crit Care. 2021;65:133–9. https://doi.org/10.1016/j.jcrc.2021.06.004
Xu F, He L-L, Che L-Q, Li W, Ying S-M, Chen Z-H, et al. Aerosolized antibiotics for ventilator-associated pneumonia: a pairwise and Bayesian network meta-analysis. Critical Care. 2018;22(1):301. https://doi.org/10.1186/s13054-018-2106-x
Moeed A, Bilal Z, Batool F, Batool Zaidi A, Arsalan Jamil M, Surani S. Role of Amikacin in the Management of Ventilator-Associated Pneumonia [Internet]. Recent Updates in Intensive Care Medicine. IntechOpen; 2024. Available from: http://dx.doi.org/10.5772/intechopen.1005446
Tavernier E, Barbier F, Meziani F, Quenot JP, Herbrecht JE, Landais M, et al. Inhaled amikacin versus placebo to prevent ventilator-associated pneumonia: the AMIKINHAL double-blind multicentre randomised controlled trial protocol. BMJ Open. 2021;11(9):e048591. https://doi.org/10.1136/bmjopen-2020-048591
Motos A, Yang H, Li Bassi G, Yang M, Meli A, Battaglini D, et al. Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia. Crit Care. 2023;27(1):60. https://doi.org/10.1186/s13054-023-04331-x
Stokker J, Karami M, Hoek R, Gommers D, van der Eerden M. Effect of adjunctive tobramycin inhalation versus placebo on early clinical response in the treatment of ventilator-associated pneumonia: the VAPORISE randomized-controlled trial. Intensive Care Med. 2020;46:546–8. https://doi.org/10.1007/s00134-019-05914-5
Ehrmann S, Barbier F, Demiselle J, Quenot JP, Herbrecht JE, Roux D, et al. Inhaled amikacin to prevent ventilator-associated pneumonia. N Engl J Med. 2023;389(22):2052–62. https://doi.org/10.1056/NEJMoa2310307
Desgrouas M, Ehrmann S. Inhaled antibiotics during mechanical ventilation—why it will work. Ann Transl Med. 2021;9(7):1–3 https://doi.org/10.21037/atm-20-3686
Boisson M, Bouglé A, Sole-Lleonart C, Dhanani J, Arvaniti K, Rello J, et al. Nebulized antibiotics for healthcare- and ventilator-associated pneumonia. Semin Respir Crit Care Med. 2022;43(2):255–70. https://doi.org/10.1055/s-0041-1740340
This work is licensed under a 